Page 227 - Mployee Wellness Programs News Today

November is National Family Caregivers Month in the US, an opportunity to honor those who have taken on this critical role of caring for loved ones, while raising awareness of the challenges they face daily and what needs to be done to drive tangible changes.

CSL Behring's hemophilia B gene therapy, Hemgenix, carries a $3.5 million list price. But the company contends that by reducing economic burdens associated with bleeding and prophylactic infusions, the one-time treatment will save money over time.

This represents a 17% increase in total ACA plan selections — both through HealthCare.gov and state-based Marketplaces — compared with last year, CMS said. Enrollment through the federal HealthCare.gov has especially seen a rise of 40% from the same period last year.

Third Culture Capital (3CC) is a venture capital firm founded with the mission to foster more equity and diversity in health technology innovation. 3CC Founder and Managing Partner said the firm is intentional about connecting to the “unique lived experiences” of the founders it invests in, as this approach ensures that it is not just checking its diversity boxes.

Among the takeaways from HLTH 2022 were the impact of consolidation on clinicians, behavioral health tools to help consumers manage stress and anxiety more productively, and how health tech and medtech companies are supporting remote patient monitoring and testing.

Practices don’t need to lose out on uncollected payments from insurers. Here are steps you can take to better manage coding, tracking, communications and rise above byzantine insurance practices.

CardieX, a cardiovascular technology company based in both Australia and Illinois, recently acquired Blumio, a San Mateo, California-based startup focused on cardiovascular sensors. The deal will advance both companies’ vision to accurately and easily measure blood pressure without relying on the use of a cuff.

When the federal government enacted the No Surprises Act to lessen payment disputes between a patient or a health insurance plan and a provider, the government projected 22,000 disputes in 2022. However, between just April and September there were more than 90,000 disputes filed. 

Telaria is developing a gene therapy for the rare skin disorder recessive dystrophic epidermolysis bullosa. The company was formed by Replay, a gene therapy biotech that forms subsidiaries that leverage its platform technologies for writing and delivering genetic medicines.

We're now accepting applications for INVEST Pitch Perfect, scheduled for May 22-24 at the Ritz Carlton in Chicago. The contest will spotlight novel healthcare startups across five categories: biopharma, diagnostics, medical devices, health tech: consumers/employers, health tech: payers/providers. Register and submit your application today.